Armand Bensussan

USPTO Granted Patents = 20 (Patent Applications = 27)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 32)

Average Co-Inventor Count = 3.8

ph-index = 8

Forward Citations = 124(Granted Patents)

Location History:

Paris, FR (2008 - 2022)
Creteil, FR (2010 - 2023)

Company Filing History:

17 out of 1,743

Institut National De La Sante Et De La Recherche Medicale

Medecine Et Innovation

patents

6. 2 out of 5,072

Centre National De La Recherche Scientifique

patents

7. 1 out of 1,207

Dana-farber-cancer Institute Inc.

patents

8. 1 out of 1

Monoclonal Antibodies Therapeutics

patent

9. 1 out of 37

Inserm (institut National De La Sante Et De La Recherche Medicale)

patents

10. 1 out of 103

Université Paris Diderot-Paris 7

patents

11. 1 out of 278

Universitè De Montpellier

patents

12. 1 out of 1

Institut Jean Godinot

patent

13. 1 out of 1

Institut RÉgional Du Cancer De Montipellier

patent

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319745 - Antibodies having specificity for CD38 and uses thereof (2025-06-03),

2. 11685792 - Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity (2023-06-27),

3. 11365392 - Ex vivo generation of MHCII restricted CD4FOXP3regulatory T cells and therapeutic uses thereof (2022-06-21),

4. 11198851 - Ex vivo generation of γδ Foxp3regulatory T cells and therapeutic uses thereof (2021-12-14),

5. 11186635 - Monoclonal antibodies binding to the CD160 transmembrane isoform (2021-11-30),

6. 10662253 - Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity (2020-05-26),

7. 10351623 - Antagonists of IL-17 isoforms and their uses (2019-07-16),

8. 10208124 - Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis (2019-02-19),

9. 9834601 - Antagonists of IL-17 isoforms and their uses (2017-12-05),

10. 9676847 - IL-17 antagonist antibodies (2017-06-13),

11. 9045544 - Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis (2015-06-02),

12. 8518655 - Means for the diagnosis and therapy of CTCL (2013-08-27),

13. 8444978 - Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 (2013-05-21),

14. 8409573 - Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells (2013-04-02),

15. 8268308 - Means for the diagnosis and therapy of CTCL (2012-09-18),

Title: The Innovative Mind of Armand Bensussan

Introduction: Armand Bensussan, a visionary inventor hailing from Paris, FR, has made significant contributions to the world of technology and innovation through his groundbreaking creations.

Latest Patents: Armand Bensussan's latest patents focus on renewable energy solutions, with a series of inventions aimed at harnessing solar power more efficiently and sustainably.

Career Highlights: With a career spanning over two decades, Armand Bensussan has established himself as a leading figure in the field of clean energy technology. His innovative designs have revolutionized the way we approach environmental sustainability.

Collaborations: Throughout his career, Armand Bensussan has collaborated with top research institutions and universities to further his inventions. His partnerships have led to the development of cutting-edge technologies that are shaping the future of renewable energy.

Conclusion: Armand Bensussan's passion for innovation and commitment to creating a more sustainable world have solidified his reputation as a pioneering inventor in the realm of clean energy technology. His contributions continue to inspire and drive progress in the industry.

This text is generated by artificial intelligence and may not be accurate.